Full Answer
Is Zom a good stock to buy now?
ZOM's strongest trending metric is Sentiment; it's been moving down over the last 34 weeks. ZOM's current lowest rank is in the Stability metric (where it is better than 1.89% of US stocks). ZOM's price/sales ratio is 18,926.23; that's higher than the P/S ratio of 99.78% of US stocks.
Is zomedica (Zom) a great growth stock?
Founded in 2013 and publicly-traded since 2016, Zomedica (ZOM) is a relatively new organization. However, this veterinary-focused medical device company has seen tremendous interest among growth investors of late.
Is Zom stock a near-10 bagger in five weeks?
Since opening the year at around $0.35 per share, ZOM stock soared to a high of $2.91 on February 8th. Any stock that’s a near-10 bagger in five weeks certainly fits the description of a
What does Zom stand for?
ANN ARBOR, MI / ACCESSWIRE / January 27, 2022 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering diagnostic and therapeutic products for companion animals, today provided an update on its marketing activities during the first quarter of 2022.
Is ZOM a good stock to buy?
Zomedica Corp (NYSE American:ZOM) The 1 analysts offering 12-month price forecasts for Zomedica Corp have a median target of 1.20, with a high estimate of 1.20 and a low estimate of 1.20. The median estimate represents a +358.19% increase from the last price of 0.26.
Why is ZOM dropping?
CEO Robert Cohen said the move was precipitated by "changes at our current distributor that we believe have impacted its ability to market our products effectively." Those words likely startled investors, many of whom decided to sell their shares. Zomedica's stock price dropped sharply on Thursday.
Is ZOM stock a buy or sell?
USD 0.25 0.01 3.85% Considering the 90-day investment horizon and your above-average risk tolerance, our recommendation regarding Zomedica Pharmaceuticals Corp is 'Strong Sell'.
What is the future of Zomedica stock?
The forecasted Zomedica price at the end of 2022 is $0.40 - and the year to year change +31%. The rise from today to year-end: +27%. In the middle of 2022, we expect to see $0.31 per 1 Zomedica.
Will ZOM ever recover?
ZOM stock will likely struggle to recover in price over the next few months. It's going to be awhile before this early stage company will again have the chance to prove itself to investors. Having said that, investors with a high appetite for risk, and a willingness to go against the grain, may want to buy today.
Will ZOM ever go back up?
There is potential for a short term uptick in the Zom stock price, especially as the active weekly candle is mildly bullish. The relative strength index is relatively oversold and has been for quite some time. A mild divergence also supports the notion of a slight recovery in the Zom stock price in the near term.
Is Zomedica being shorted?
What is Zomedica's current short interest? Short interest is the volume of Zomedica shares that have been sold short but have not yet been covered or closed out. As of May 15th, traders have sold 112,640,000 shares of ZOM short. 11.68% of Zomedica's shares are currently sold short.
Is Truforma FDA approved?
In April 2020, Zomedica announced that they had completed platform verification of TRUFORMA, which confirms the achievement of instrument design specifications, and follows FDA Medical Device design control guidelines to ensure the product was built correctly.
What is NAKD stock?
Key Turning Points52-Week High51.00Fibonacci 50%26.80Fibonacci 38.2%21.09Last Price2.6152-Week Low2.601 more row•Jan 13, 2022
What is Nio price target?
Stock Price Forecast The 29 analysts offering 12-month price forecasts for NIO Inc have a median target of 31.54, with a high estimate of 82.90 and a low estimate of 23.06. The median estimate represents a +74.36% increase from the last price of 18.09.
Is TXMD a buy?
TherapeuticsMD has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Will AMC stock go up?
Deflating the short interest Deflating AMC's short interest like we saw back in January and June means AMC stock will go up significantly higher from its current share price. Small short covering allowed AMC to reach $72 per share back in June of 2021.
Are investors shorting Zomedica?
Zomedica saw a increase in short interest in May. As of May 15th, there was short interest totaling 112,640,000 shares, an increase of 23.4% from t...
When is Zomedica's next earnings date?
Zomedica is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022. View our earnings forecast for Zomedica .
How were Zomedica's earnings last quarter?
Zomedica Corp. (NYSEAMERICAN:ZOM) posted its quarterly earnings data on Thursday, November, 12th. The company reported ($0.01) earnings per share (...
What guidance has Zomedica issued on next quarter's earnings?
Zomedica issued an update on its FY 2021 earnings guidance on Monday, March, 21st. The company provided earnings per share (EPS) guidance of for th...
Who are Zomedica's key executives?
Zomedica's management team includes the following people: Ms. Ann Marie Cotter CPA , CFO & Sec. (Age 51) Dr. Stephanie Laine Morley D.V.M. , DV...
Who are some of Zomedica's key competitors?
Some companies that are related to Zomedica include Syndax Pharmaceuticals (SNDX) , Procaps Group (PROC) , Kura Oncology (KURA) , Morphic (MORF...
What is Zomedica's stock symbol?
Zomedica trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ZOM."
Who are Zomedica's major shareholders?
Zomedica's stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (4.14%), Stat...
Which major investors are selling Zomedica stock?
ZOM stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Vanguard Group Inc., Bank of New York...
How many shares were in Zomedica on Nov 12?
On Nov. 12, the volume in Zomedica stock was about 15.8 million shares. Given that ZOM traded at about eight cents that day, we’re looking at total dollar trading in the range of $1 million. On Nov. 13, however, ZOM saw volume of over 253 million shares.
How much did Baskin pay for Zomedica?
Someone paid Baskin $299 to tout Zomedica on video-sharing platform Cameo. In response, the stock rose 171% over the two sessions. The Good News Admittedly, a long-term investor can look at Zomedica and see some reason for optimism, though.
How much is AMC worth in 2020?
At the beginning of 2020, before the novel coronavirus pandemic hit, AMC was worth less than $1 billion. In fact, even with the balance sheet moves, AMC now has a higher enterprise value (market capitalization plus net debt) than it did at the beginning of 2020. It’s hard to see how that makes sense.
Is Zomedica the next IDEXX?
Zomedica has a lot of work ahead of it before it’s even close to becoming the next IDEXX. In the meantime, the company still needs to execute the commercialization of Truforma. If it experiences any hiccups along the way, shares could fall back to lower price levels. Reconsider ZOM stock as a buy if that happens.
Is GameStop going to rebound in 2021?
In fact, bulls argued, they were a sign of the end of the console cycle. With new consoles coming from Sony (NYSE:SNE) and Microsoft (NASDAQ:MSFT), earnings would quickly rebound in 2021 and beyond.
Is Baskin paid to promote the stock?
While it turns out Baskin was paid to promote the stock, there is another upcoming and more tangible catalyst for investors to get behind; this is due to the upcoming launch of Truforma, Zomedica’s point-of-care (POC) diagnostic device for the detection of thyroid disease in dogs and cats and adrenal disease in dogs.
Does Thomas Niel hold any positions in the securities mentioned in this article?
On the date of publication, Thomas Niel did not (either directly or indirectly) hold any positions in the securities mentioned in this article. Thomas Niel, a contributor to InvestorPlace, has written single stock analysis since 2016.
What is Zomedica Corp?
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA, a diagnostic biosensor platform for the detection of thyroid disorders in dogs and cats, and adrenal disorders in dogs. It has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.
Where does Zomedica trade?
Zomedica trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ZOM."
What is the P/E ratio of Zomedica?
The P/E ratio of Zomedica is -7.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Is there enough data for Zomedica?
There is not enough analysis data for Zomedica.
Does Zomedica pay dividends?
Zomedica does not currently pay a dividend.
How do hedge funds control the price?
very common strategy to be used by hedge funds to control the price. simply buy and hold, this price is a discount. good luck.
Is Zomedica a good stock?
Zomedica being added to MSCI proves it's seen as a growth stock, potentially even having dividends in the future. This addition can potentially increase trading and volume. The MSCI indexes are similar to the Dow Jones Averages or the S&P 500. This is very good news.
Is a zom part of an index?
Remember ZOM is part of an index. Institutions buy the underlying symbols in the index. Hence a vast majority of institutions hold ZOM.
How much is Zomedica stock worth in 2021?
The Zomedica Pharmaceuticals Corp stock price gained 3.73% on the last trading day (Friday, 9th Jul 2021), rising from $0.71 to $0.74. During the day the stock fluctuated 4.11% from a day low at $0.72 to a day high of $0.75. The price has fallen in 6 of the last 10 days and is down by -12.33% for this period. Volume fell on the last day by -6 million shares and in total, 18 million shares were bought and sold for approximately $13.09 million. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.
Is Zomedica Pharmaceuticals Corp a negative stock?
Zomedica Pharmaceuticals Corp holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Sell to a Strong Sell candidate.
What is the quality of ZOM?
ZOM has a Quality Grade of F , ranking ahead of 3.62% of graded US stocks.
How volatile is Zom?
In terms of volatility of its share price, ZOM is more volatile than 98.88% of stocks we're observing.
What is Zomedica Pharmaceuticals?
Zomedica Pharmaceuticals Corp. operates as a veterinary pharmaceutical company in the United States. It focuses on the discovery, development, and commercialization of drugs, novel drug delivery systems, devices, and diagnostics for the health and wellness of companion animals, such as canine, feline, and equine.
Why did Zomedica stock fall?
The tepid sales growth left the market disappointed and ZOM stock fell after the earnings release. Zomedica said that its revenue was lower in the quarter due to delays by its partner in developing fT4 and ACTH assays. It said that ft4 assays would be available by the fall, and ACTH by the end of 2021.
How many shares did Zom short on Aug 25?
According to data from Fintel, on Aug. 25, ZOM had a total FINRA short volume of 52.5 million shares on Aug. 25—up over sixfold from the previous day. However, ZOM's FINRA short volume as a percentage of total volumes was 55 percent, only slightly higher than the previous day's 53 percent.
